The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential.
about
The Apelin-APJ System in the Evolution of Heart FailureApelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular systemRegulation of vascular tone by adipocytes.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsOverexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver.Association of genetic variants in the apelin-APJ system and ACE2 with blood pressure responses to potassium supplementation: the GenSalt studyAngiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.Modulation of the apelin/APJ system in heart failure and atherosclerosis in manApelin receptor (APJ) expression during cardiopulmonary bypass in children undergoing surgical repair.Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity.Apelin and pulmonary hypertension.Genetic differences and aberrant methylation in the apelin system predict the risk of high-altitude pulmonary edema.Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention.Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction.Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia-induced lung injury in neonatal rats.Therapeutic efficacy of apelin on transplanted mesenchymal stem cells in hindlimb ischemic mice via regulation of autophagy.Lactation Is a Risk Factor of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ) Overexpression.The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic Peptide release.Getting the message across: mechanisms of physiological cross talk by adipose tissue.Effect of Spironolactone on Plasma Apelin-12 Levels in Patients with Chronic Systolic Heart FailureBiased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and PathologyFetal and maternal hemodynamics in pregnancy: new insights in the cardiovascular adaptation to uncomplicated pregnancy, twin-to-twin transfusion syndrome and congenital diaphragmatic hernia.Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR).NMDA receptor modulation by the neuropeptide apelin: implications for excitotoxic injuryLungs at high-altitude: genomic insights into hypoxic responses.Possible involvement of downregulation of the apelin-APJ system in doxorubicin-induced cardiotoxicity.Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1.Influence of apelin-12 on troponin levels and the rate of MACE in STEMI patients.Apelin attenuates hyperoxic lung and heart injury in neonatal rats.Commentary: Acute Myocardial Response to Stretch: What We (don't) Know.Effect of the spinal apelin‑APJ system on the pathogenesis of chronic constriction injury‑induced neuropathic pain in rats.By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization.Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy.Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B.The effects of apelin treatment on skeletal muscle mitochondrial content.Individual and concomitant effects of cardioprotective programs on cardiac apelinergic system and oxidative state in L-NAME-induced hypertension.Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion.Predictive value of apelin-12 in patients with ST-elevation myocardial infarction with different renal function: a prospective observational study.Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications.Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy.
P2860
Q26777306-96854162-E4BE-4987-B0A9-51E9D3F6FAA6Q26823618-457AAB7B-3BEB-462C-97DE-0785A0624179Q27691400-26F2755E-FFBE-4A4B-AD25-A78A8449A9C8Q30486707-7C777963-D553-4FEB-8E6E-0BEEEA96381DQ33666996-E741EF46-F3D6-4D0F-9DE7-A78A7EAC5BCAQ33932245-DB709D85-58C8-45D5-9B5E-ED94F4EA2153Q34001678-26B60B72-54F2-4E59-84DD-256DC0C60001Q34116830-CD3E5C09-A4F7-46D4-8BF9-771CCC54C820Q34128580-D65EFDE0-0CC2-4324-97D6-27DCBB5E89C1Q35046722-D6A3C201-B8EF-455C-A754-FBE60FA9C10DQ35573931-71E3FA15-58B2-4EC4-9288-A750DC460418Q35616324-12972FAB-C886-4DFF-A551-94DF9C1101FFQ36153309-7F3170D1-94E0-4987-A9A0-66A12B8E5307Q36309299-989F1660-C513-4DC2-8902-6C8ADAEFA74DQ36535430-FF91B0A1-6911-4C13-B452-278965134B83Q36605872-E81A00B2-6DAA-4741-8EAA-ABF848C06256Q36987681-93598A6F-5321-45CE-ADC6-2A0EDA30FBA5Q37161749-537EFC1C-9553-4800-B7A3-539A7CB77D8DQ37405747-14ED1DBC-6405-4934-AFA9-4704F0354EFCQ37448653-FCF49C7D-661D-49B8-BC6B-2E39E646700DQ37551908-9EDBA517-6B13-4366-A510-2E624652E516Q37709914-000E6FA4-FB78-4031-B3E2-853BD59F427BQ38267493-F1ADD791-A32C-422C-B95B-1687FCD9E7A6Q38295226-907DE10D-A241-46DD-B545-34C87D2E9FBDQ38441794-8C862533-702A-4809-9D67-7378750791C9Q38909771-648A978A-EE2B-42AD-8350-659909251394Q39693574-17AC2554-282C-4191-80CD-A977EDBEE582Q41079347-9D3564C7-C66B-4F78-94DD-A197591E2018Q41137848-6E7D479A-9C58-4763-89C0-2142EBD76D1EQ41844719-6DE366AF-5030-401A-91C1-891D70739EC7Q42347144-6BA8B717-21A8-4AA5-B850-54C76D77B06AQ42411890-E111D318-961A-4DB3-959F-569D7856CAE4Q43096140-199D4FCE-725A-4132-8D93-992F0B104DC1Q43251720-29517F49-4554-475F-8CFF-70B2ACABEE5DQ43268962-B24E4853-0065-4114-A8B5-FC5B7D515019Q44736928-D978AF3F-90CE-4F7E-AF34-AFAF7CEDCFB9Q46923255-6B9836D1-F8FF-4FD8-B9B9-059E58266A7DQ47117248-432DF9B3-20A5-4186-A426-7A9C94F51C71Q47733807-E9CCDCF6-5DEF-45D0-88DA-825960640B63Q48596951-DF99ED47-A867-42CD-86D8-A2FB5E4B3703
P2860
The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The apelin-APJ system in heart ...... nce and therapeutic potential.
@en
The apelin-APJ system in heart ...... nce and therapeutic potential.
@nl
type
label
The apelin-APJ system in heart ...... nce and therapeutic potential.
@en
The apelin-APJ system in heart ...... nce and therapeutic potential.
@nl
prefLabel
The apelin-APJ system in heart ...... nce and therapeutic potential.
@en
The apelin-APJ system in heart ...... nce and therapeutic potential.
@nl
P1476
The apelin-APJ system in heart ...... nce and therapeutic potential.
@en
P2093
Alan G Japp
David E Newby
P304
P356
10.1016/J.BCP.2007.12.015
P407
P577
2008-01-05T00:00:00Z